Published in Am J Pathol on November 01, 1997
VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A (2002) 8.10
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis (2014) 2.07
Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications. Am J Pathol (2007) 1.99
Molecular biology of breast cancer metastasis. Molecular expression of vascular markers by aggressive breast cancer cells. Breast Cancer Res (2000) 1.84
Controlling escape from angiogenesis inhibitors. Nat Rev Cancer (2012) 1.81
Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Rev (2007) 1.76
Intra-tumoural microvessel density in human solid tumours. Br J Cancer (2002) 1.60
Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer (2000) 1.57
Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. Genes Cancer (2010) 1.54
Antiangiogenic therapy--evolving view based on clinical trial results. Nat Rev Clin Oncol (2012) 1.51
Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia. Br J Cancer (2004) 1.44
Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. J Exp Med (2010) 1.41
Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment? Cancer Med (2013) 1.36
Tumor Spread through Air Spaces is an Important Pattern of Invasion and Impacts the Frequency and Location of Recurrences after Limited Resection for Small Stage I Lung Adenocarcinomas. J Thorac Oncol (2015) 1.24
Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br J Cancer (2005) 1.24
Inflammatory breast cancer: vasculogenic mimicry and its hemodynamics of an inflammatory breast cancer xenograft model. Breast Cancer Res (2003) 1.24
A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cells. Breast Cancer Res (2006) 1.24
Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model. Neuro Oncol (2008) 1.19
Clinicopathological significance of non-small cell lung cancer with high prevalence of Oct-4 tumor cells. J Exp Clin Cancer Res (2012) 1.17
Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer. Dose Response (2010) 1.16
Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas. Br J Cancer (2002) 1.16
A small-molecule inhibitor of the ribonucleolytic activity of human angiogenin that possesses antitumor activity. Proc Natl Acad Sci U S A (2002) 1.13
The histological growth pattern of colorectal cancer liver metastases has prognostic value. Clin Exp Metastasis (2012) 1.03
Challenges of antiangiogenic cancer therapy: trials and errors, and renewed hope. J Cell Mol Med (2007) 1.00
Contrast enhanced ultrasonography (CEUS) in peripheral lung lesions: A study of 60 cases. J Ultrasound (2008) 0.98
Fractal dimension as a quantitator of the microvasculature of normal and adenomatous pituitary tissue. J Anat (2007) 0.98
Prospective study of intratumoral microvessel density, p53 expression and survival in colorectal cancer. Br J Cancer (1999) 0.96
Extracellular protease ADAMTS9 suppresses esophageal and nasopharyngeal carcinoma tumor formation by inhibiting angiogenesis. Cancer Res (2010) 0.95
Thymidine kinase 1 and thymidine phosphorylase expression in non-small-cell lung carcinoma in relation to angiogenesis and proliferation. J Histochem Cytochem (2009) 0.95
The clinical potential of antiangiogenic fragments of extracellular matrix proteins. Br J Cancer (2005) 0.92
Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma. J Natl Cancer Inst (2016) 0.92
Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases. Br J Cancer (2011) 0.91
Relative microvessel area of the primary tumour, and not lymph node status, predicts the presence of bone marrow micrometastases detected by reverse transcriptase polymerase chain reaction in patients with clinically non-metastatic breast cancer. Breast Cancer Res (2005) 0.90
Contrast-enhanced ultrasonography in peripheral lung consolidations: What's its actual role? World J Radiol (2013) 0.89
Angiogenic switch during tumor progression of carcinoma ex-pleomorphic adenoma. Virchows Arch (2007) 0.88
Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumors. Am J Transl Res (2015) 0.87
Is nonangiogenesis a novel pathway for cancer progression? A study using 3-dimensional tumour reconstructions. Br J Cancer (2006) 0.86
Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models. J Pathol (2016) 0.85
Inhibition of epidermoid carcinoma A431 cell growth and angiogenesis in nude mice by early and late treatment with a novel dextran derivative. Br J Cancer (2003) 0.84
Angiogenesis: multiple masks in hepatocellular carcinoma and liver regeneration. Hepatol Int (2010) 0.84
Dynamic contrast-enhanced CT to assess metabolic response in patients with advanced non-small cell lung cancer and stable disease after chemotherapy or chemoradiotherapy. Eur Radiol (2013) 0.80
Angiogenesis in NSCLC: is vessel co-option the trunk that sustains the branches? Oncotarget (2017) 0.80
Redirecting Transport of Nanoparticle Albumin-Bound Paclitaxel to Macrophages Enhances Therapeutic Efficacy against Liver Metastases. Cancer Res (2016) 0.79
Why some tumours trigger neovascularisation and others don't: the story thus far. Chin J Cancer (2016) 0.79
Evidence Showing That Tumors Can Grow Without Angiogenesis and Can Switch Between Angiogenic and Nonangiogenic Phenotypes. J Natl Cancer Inst (2016) 0.79
Mechanisms of vascularization in murine models of primary and metastatic tumor growth. Chin J Cancer (2016) 0.79
Current status and perspective of angiogenesis and antivascular therapeutic strategy: non-small cell lung cancer. Int J Clin Oncol (2006) 0.78
Enhanced performance of macrophage-encapsulated nanoparticle albumin-bound-paclitaxel in hypo-perfused cancer lesions. Nanoscale (2016) 0.78
Angiogenesis in Paget's Disease of the Vulva and the Breast: Correlation with Microvessel Density. J Oncol (2012) 0.78
Prognostic value of nonangiogenic and angiogenic growth patterns in non-small-cell lung cancer. Br J Cancer (2004) 0.77
Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer (2017) 0.76
Resistance to anti-angiogenic agents: a brief review of mechanisms and consequences. Transl Lung Cancer Res (2013) 0.76
Adenoviral gene transfer of angiostatic ATF-BPTI inhibits tumour growth. BMC Cancer (2002) 0.75
Blood vessels and cancer much more than just angiogenesis. Cell Death Discov (2015) 0.75
Antiangiogenic tyrosine kinase inhibitors in non-small-cell-lung cancer: lights and shadows. Transl Lung Cancer Res (2013) 0.75
The Way that PEGyl-DSPC Liposomal Doxorubicin Particles Penetrate into Solid Tumor Tissue. Drug Target Insights (2006) 0.75
Twenty years after: the beautiful hypothesis and the ugly facts. Chin J Cancer (2016) 0.75
Bronchial Artery Angiogenesis Drives Lung Tumor Growth. Cancer Res (2016) 0.75
Fine-Tuning Tumor Endothelial Cells to Selectively Kill Cancer. Int J Mol Sci (2017) 0.75
Tumor angiogenesis: therapeutic implications. N Engl J Med (1971) 35.36
Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology (1991) 30.87
What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst (1990) 13.41
Antigen unmasking on formalin-fixed, paraffin-embedded tissue sections. J Pathol (1993) 6.15
Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation. Am J Pathol (1990) 4.42
Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol (1995) 4.37
Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet (1992) 3.77
Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochim Biophys Acta (1990) 3.18
JC70: a new monoclonal antibody that detects vascular endothelium associated antigen on routinely processed tissue sections. J Clin Pathol (1990) 3.10
Tumor angiogenesis in human lung adenocarcinoma. Cancer (1994) 2.59
Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. J Pathol (1995) 2.52
Biology of tumour metastasis. Lancet (1992) 2.44
Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol (1995) 1.81
Angiogenesis and metastasis. Eur J Cancer (1996) 1.72
Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol (1997) 1.55
Tumor angiogenesis: review of current applications in tumor prognostication. Semin Diagn Pathol (1993) 1.46
Prognostic value of angiogenesis in operable non-small cell lung cancer. J Pathol (1996) 1.42
Microvessel count predicts metastatic disease and survival in non-small cell lung cancer. J Pathol (1995) 1.40
Tumor angiogenesis, the p53 antigen, and cervical metastasis in squamous carcinoma of the tongue. Otolaryngol Head Neck Surg (1994) 1.31
Angiogenesis: an indicator of metastasis in non-small cell lung cancer invading the thoracic inlet. Ann Thorac Surg (1994) 1.13
Clinical prognostic significance of tumour angiogenesis. Ann Oncol (1994) 1.11
Angiogenesis in primary lung cancer and lung secondaries. Eur J Cancer (1996) 1.11
The histologic grading of cancer. Cancer (1995) 1.06
Characterization of two monoclonal antibodies directed against the 67 kDa high affinity laminin receptor and application for the study of breast carcinoma progression. Clin Exp Metastasis (1992) 0.98
Tumor angiogenesis correlates with histologic type and metastasis in non-small-cell lung cancer. Am J Respir Crit Care Med (1995) 0.91
Immunohistochemical evidence that lung carcinomas grow on alveolar basement membranes. Am J Surg Pathol (1990) 0.89
Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med (1996) 22.46
A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood (1994) 21.00
A physical map of 30,000 human genes. Science (1998) 12.43
Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst (1992) 8.69
Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med (1981) 7.53
Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res (2000) 5.74
Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci U S A (1997) 5.42
Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res (1996) 5.38
An immunohistochemical study of the pathology of fatal malaria. Evidence for widespread endothelial activation and a potential role for intercellular adhesion molecule-1 in cerebral sequestration. Am J Pathol (1994) 5.34
The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol (2000) 5.21
The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med (1995) 4.75
Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet (1990) 4.49
Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg (1997) 4.47
Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation. Am J Pathol (1990) 4.42
Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet (1987) 4.28
Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology (2002) 4.22
Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet (1992) 4.10
bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med (1993) 4.05
Equilibrium properties of a voltage-dependent junctional conductance. J Gen Physiol (1981) 3.91
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol (1998) 3.79
Results of a breast-cancer-surgery trial compared with observational data from routine practice. Lancet (1996) 3.78
Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha. Blood (1998) 3.67
Diagnosis of human lymphoma with monoclonal antileukocyte antibodies. N Engl J Med (1983) 3.63
Ki67 protein: the immaculate deception? Histopathology (2002) 3.61
Radiotherapy after breast-preserving surgery in women with localized cancer of the breast. N Engl J Med (1993) 3.54
The Bloom's syndrome gene product interacts with topoisomerase III. J Biol Chem (2000) 3.52
P53 expression in breast cancer. Int J Cancer (1988) 3.51
Transferrin receptor on endothelium of brain capillaries. Nature (1984) 3.37
Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res (1989) 3.35
Kinetic properties of a voltage-dependent junctional conductance. J Gen Physiol (1981) 3.33
HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res (2001) 3.27
Updated Kiel classification for lymphomas. Lancet (1988) 3.25
Transferrin receptors in human tissues: their distribution and possible clinical relevance. J Clin Pathol (1983) 3.23
Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer (2001) 3.10
JC70: a new monoclonal antibody that detects vascular endothelium associated antigen on routinely processed tissue sections. J Clin Pathol (1990) 3.10
Center for Birth Defects Information Services. Birth Defects Orig Artic Ser (1980) 3.09
Monoclonal antibody Ki-67: its use in histopathology. Histopathology (1990) 3.07
Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer (1996) 3.07
Immunocytochemical localization of the cystic fibrosis gene product CFTR. Proc Natl Acad Sci U S A (1991) 2.82
KP1: a new monoclonal antibody that detects a monocyte/macrophage associated antigen in routinely processed tissue sections. J Clin Pathol (1989) 2.82
Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer (2002) 2.82
EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the EUropean Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J Natl Cancer Inst (2000) 2.77
Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet (1985) 2.76
PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol (2008) 2.75
Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol (2001) 2.71
Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology (2006) 2.70
Use of monoclonal antibodies for the histopathological diagnosis of human malignancy. J Clin Pathol (1982) 2.69
TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med (1998) 2.68
Fraud in medical research: an international survey of biostatisticians. ISCB Subcommittee on Fraud. Control Clin Trials (2000) 2.67
Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res (2001) 2.66
Gap junctional conductance is a simple and sensitive function of intracellular pH. Science (1981) 2.64
A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases. Nature (1987) 2.60
eIF4E expression in tumors: its possible role in progression of malignancies. Int J Biochem Cell Biol (1999) 2.57
Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events. J Natl Cancer Inst (1995) 2.52
Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. J Pathol (1995) 2.52
Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br J Cancer (1999) 2.47
Leptin secretion and leptin receptor in the human stomach. Gut (2000) 2.46
Epidermal-growth-factor receptors and oestrogen receptors in human breast cancer. Lancet (1985) 2.44
Immunohistological analysis of human mononuclear phagocytes and dendritic cells by using monoclonal antibodies. Lab Invest (1986) 2.42
Peripheral T-cell lymphoma associated with hemophagocytic syndrome. Blood (1990) 2.40
Clinical importance of analysing malignant tumours of uncertain origin with immunohistological techniques. Lancet (1985) 2.40
Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res (2001) 2.38
Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J Pathol (2008) 2.37
The FHIT gene 3p14.2 is abnormal in lung cancer. Cell (1996) 2.36
Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc Natl Acad Sci U S A (1997) 2.36
Transient increase in phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol trisphosphate during activation of human neutrophils. J Biol Chem (1989) 2.35
Breast conservation is a safe method in patients with small cancer of the breast. Long-term results of three randomised trials on 1,973 patients. Eur J Cancer (1995) 2.30
c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer (1991) 2.29
Improved predictive testing for Huntington disease by using three linked DNA markers. Am J Hum Genet (1988) 2.28
Breast cancer patients treated without axillary surgery: clinical implications and biologic analysis. Ann Surg (2000) 2.27
Vascular endothelial growth factor platelet counts, and prognosis in renal cancer. Lancet (1999) 2.26
Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst (1990) 2.25
Human lymphoid cells express epithelial membrane antigen. Implications for diagnosis of human neoplasms. Lancet (1984) 2.25
Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol (2004) 2.24
Percutaneous treatment of small hepatic tumors by an expandable RF needle electrode. AJR Am J Roentgenol (1998) 2.23
Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer (1996) 2.23
Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. Cancer Res (1994) 2.21
Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer (2003) 2.20
Association between platelet microthrombi and finger clubbing. Lancet (1991) 2.20
Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. J Pathol (2000) 2.18